Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Palmoplantar pustulosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK

Most Recent Events

  • 12 Aug 2021 Results of pool analysis from phase 2 (NCT01845987) and phase 3 (NCT02641730) of guselkumab, assessing the longitudinal profile of PPPASI score improvement by guselkumab treatment and clinical implications of guselkumab dose, baseline disease severity and smoking on the treatment effect, by using pharmacokinetic and pharmacodynamic modeling, published in the Journal of Clinical Pharmacology.
  • 07 Feb 2018 Primary endpoint (Change from baseline in PPSI total score at Week 16) has been met, according to results published in the JAMA Dermatology.
  • 07 Feb 2018 Results published in the JAMA Dermatology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top